
Cellink AB acquires Ginolis Oy for €70m
Under the agreement, Cellink AB is set to acquire all shares for a purchase price on cash- and debt-free basis of €70m. Forty per cent of the...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

EU orders additional COVID-19 vaccine doses
Under the new deal, the Commission has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...